A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration

ISSN： 0114-5916

Source： Drug Safety, Vol.29, Iss.3, 2006-01, pp. : 189-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Verteporfin worth it for age-related macular degeneration in the UK?

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration

By Gaynes Bruce I Fiscella Richard G

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 345-361

Informa Healthcare

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K. Jones Mechelle L. Halpern Michael T.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite

Does aspirin increase the risk of age-related macular degeneration?

By Chong Elaine W Guymer Robyn H Robman Liubov D

Expert Opinion on Drug Safety, Vol. 13, Iss. 6, 2014-06 ,pp. : 691-693

Informa Healthcare

Access to resources Recommend Favorite

A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation

By Cahill Kate Stead Lindsay Lancaster Tim

Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. : 119-135

Adis International

Access to resources Recommend Favorite